Loading, Please Wait...
OCALA, Fla., April 25, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019, at 8:30 a.m. PT.
The conference will be held April 30-May 2, 2019 at Bally’s Hotel & Casino in Las Vegas, Nevada. The live webcast of the presentation, and an archived video afterward, will be available here: https://www.webcaster4.com/Webcast/Page/2059/30408
Equels' presentation will focus on the company’s ongoing clinical trials and programs using its flagship investigational drug Ampligen to treat multiple cancer types. The company recently announced significant progress in its Ampligen pancreatic cancer program and multiple Ampligen plus checkpoint blockade immuno-oncology programs. See here: https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-Significant-Progress-in-its-Ampligen-Pancreatic-Cancer-Program-and-Mu
In addition to his presentation, Equels will be meeting one-on-one with investors and industry representatives to discuss both the company’s successes and his plans for its future.
“Three years ago, Hemispherx identified three significant steps we needed to take to make our company a success: raise the funds necessary to produce our drug candidate, Ampligen for use in clinical trials and other programs, and utilize Ampligen in multiple immuno-oncology clinical trials,” said Equels. “We’ve since accomplished all three. Now is the time for us to seek out big pharma and other potential partners who share our excitement and enthusiasm for the potential of Ampligen.”
About Planet MicroCap Showcase
Planet MicroCap Showcase brings together promising companies with well-known and influential microcap investors, fund managers and newsletter writers for three days of company presentations, one-on-one meetings, and networking in the nation’s #1 destination for meetings and entertainment.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.